Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Viet Nam Pharmaceutical - JSC EV-to-EBITDA?
Viet Nam Pharmaceutical - JSCHSTC:DVN 82 EV-to-EBITDA is 5.51 as of Aug. 22, 2026, which is 50% below its 10-year median of 10.94. GuruFocus rates HSTC:DVN with a GF Score™ of 82/100 and a GF Value™ of ₫22,202.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks better than 82.68% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viet Nam Pharmaceutical - JSC's enterprise value is ₫4,954,569 Mil.
Viet Nam Pharmaceutical - JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₫899,608 Mil. Therefore, Viet Nam Pharmaceutical - JSC's EV-to-EBITDA for today is 5.51.
The historical rank and industry rank for Viet Nam Pharmaceutical - JSC's EV-to-EBITDA or its related term are showing as below:
HSTC:DVN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.48 Med: 10.94 Max: 23.17
Current: 5.51
During the past 7 years, the highest EV-to-EBITDA of Viet Nam Pharmaceutical - JSC was 23.17. The lowest was 5.48. And the median was 10.94.
HSTC:DVN's EV-to-EBITDA is ranked better than 82.68% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs HSTC:DVN: 5.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viet Nam Pharmaceutical - JSC's PE Ratio (TTM) for today is calculated as:
Viet Nam Pharmaceutical - JSC's share price for today is ₫18100.00.
Viet Nam Pharmaceutical - JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫2806.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's EV-to-EBITDA falls into.
Viet Nam Pharmaceutical - JSC's current Enterprise Value is ₫4,954,569 Mil.
Viet Nam Pharmaceutical - JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫899,608 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a EV-to-EBITDA of 5.51 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viet Nam Pharmaceutical - JSC. This is 50% below median its historical median of 10.94. Over the past decade, Viet Nam Pharmaceutical - JSC's EV-to-EBITDA has ranged from 5.48 to 23.17. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #128 out of 739 companies in the Drug Manufacturers industry, placing it in the top 17.3%.
Is Viet Nam Pharmaceutical - JSC's EV-to-EBITDA too high?
Viet Nam Pharmaceutical - JSC's current EV-to-EBITDA of 5.51 is 50% below median its 10-year median of 10.94. Over the past 10 years, this metric has ranged from a low of 5.48 to a high of 23.17. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Viet Nam Pharmaceutical - JSC's value of 5.51 is 57.5% below this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #128 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #128 out of 739 companies for EV-to-EBITDA. This places Viet Nam Pharmaceutical - JSC in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.97. Viet Nam Pharmaceutical - JSC's value of 5.51 is 57.5% below this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own EV-to-EBITDA has ranged from 5.48 to 23.17 over the past decade. While the company's 10-year median is 10.94 vs. the industry median of 12.97, Viet Nam Pharmaceutical - JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current EV-to-EBITDA of 5.51 is 57.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viet Nam Pharmaceutical - JSC. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current EV-to-EBITDA is 5.51, which is 50% below median its own 10-year median of 10.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,202.41, compared to a current price of ₫18,100.00 — trading 18.5% below its estimated fair value. The current EV-to-EBITDA is 5.51, which is 50% below median its 10-year median of 10.94 and 57.5% below the Drug Manufacturers industry median of 12.97. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current EV-to-EBITDA is 5.51 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫18,100.00 is trading 18.5% below its estimated GF Value™ of ₫22,202.41.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
EV-to-EBITDA: 5.51 (50% below median its 10-year median of 10.94)
GF Value™: ₫22,202.41 vs. price of ₫18,100.00 (18.5% below fair value)
Industry Position: 57.5% below the Drug Manufacturers median (#128 of 739)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
82GF Score
Get the complete analysis for HSTC:DVN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
